Risk factors predictive of anemia development during telaprevir plus peginterferon/ribavirin therapy in treatment-experienced patients

Journal of Hepatology

Volumn 60, Issue 6, 2014, Pages 1112-1117

  Zeuzem, Stefan ^a   Demasi, Ralph ^b   Baldini, Alessandra ^c   Coate, Bruce ^b   Luo, Donghan ^b   Mrus, Joseph ^b   Witek, James ^b  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^c Janssen   (France)

Author keywords

Anemia; Genotype 1; HCV; Predictor of response; REALIZE; Telaprevir

Indexed keywords

HEMOGLOBIN; PEGINTERFERON ALPHA2A; RIBAVIRIN; TELAPREVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; OLIGOPEPTIDE; RECOMBINANT PROTEIN;

AGED; ANEMIA; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EVALUATION STUDY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NOMOGRAM; PHASE 3 CLINICAL TRIAL; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT DURATION; TREATMENT FAILURE; VIRUS LOAD; ADULT; BODY MASS; DRUG TREATMENT FAILURE; FIBROSIS; GLOMERULUS FILTRATION RATE; HEPATITIS C VIRUS GENOTYPE 1; MIDDLE AGED; PATIENT MONITORING; PREDICTOR VARIABLE; PROGNOSIS; RACE; RISK ASSESSMENT; SEX; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG COMBINATION; HEPATITIS C, CHRONIC; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE; STATISTICAL MODEL; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ANEMIA; ANTIVIRAL AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; PREDICTIVE VALUE OF TESTS; RECOMBINANT PROTEINS; RIBAVIRIN; RISK FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84901244814     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.01.013     Document Type: Article

References (23)

1. I.M. Jacobson, J.G. McHutchison, G. Dusheiko, A.M. Di Bisceglie, K.R. Reddy, and N.H. Bzowej et al. Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 2011 2405 2416
2. K.E. Sherman, S.L. Flamm, N.H. Afdhal, D.R. Nelson, M.S. Sulkowski, and G.T. Everson et al. Response-guided telaprevir combination treatment for hepatitis C virus infection N Engl J Med 365 2011 1014 1024
3. J.G. McHutchison, G.T. Everson, S.C. Gordon, I.M. Jacobson, M. Sulkowski, and R. Kauffman et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection N Engl J Med 360 2009 1827 3188
4. S. Zeuzem, P. Andreone, S. Pol, I.M. Jacobson, M. Sulkowski, and R. Kauffman et al. Telaprevir for retreatment of HCV infection N Engl J Med 364 2011 2417 2428
5. J.G. McHutchison, M.P. Manns, A.J. Muir, N.A. Terrault, I.M. Jacobson, and N.H. Afdhal et al. Telaprevir for previously treated chronic HCV infection N Engl J Med 362 2010 1292 1303
6. M.G. Ghany, D.R. Nelson, D.B. Strader, D.L. Thomas, and L.B. Seeff Genotype 1 HCV treatment guidelines Hepatology 54 2011 1433 1444 [Updated at http://www.aasld.org/practiceguidelines/Documents/ AASLDUpdateTreatmentGenotype1HCV11113.pdf ]
7. EASL Clinical Practice Guidelines Management of hepatitis C virus infection J Hepatol 55 2011 245 264
8. I.M. Jacobson, K.V. Kowdley, and P.Y. Kwo Anemia management in the era of triple combination therapy for chronic HCV Gastroenterol Hepatol (N Y) 8 2012 1 16
9. M. Sherman, L. Cohen, M.A. Cooper, M. Elkashab, V. Feinman, and D. Fletcher et al. Clinical recommendations for the use of recombinant human erythropoietin in patients with hepatitis C virus being treated with ribavirin Can J Gastroenterol 20 2006 479 485
10. J.G. McHutchison, M.P. Manns, R.S. Brown Jr., K.R. Reddy, M.L. Shiffman, and J.B. Wong Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy Am J Gastroenterol 102 2007 880 889
11. N. Reau, S.J. Hadziyannis, D. Messinger, M.W. Fried, and D.M. Jensen Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin Am J Gastroenterol 103 2008 1981 1988
12. F. Suzuki, Y. Suzuki, N. Akuta, H. Sezaki, M. Hirakawa, and Y. Kawamura et al. Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir Hepatology 53 2011 415 421
13. S. Roberts, P. Andreone, S. Pol, Z. Younossi, M. Diago, and E.L. Lawitz et al. Impact of anemia and ribavirin dose reduction on SVR to a telaprevir-based regimen in patients with HCV genotype 1 and prior peginterferon/ribavirin treatment failure in the Phase III REALIZE Study Hepatology 54 Suppl. 2011 253A
14. E. Snoeck, J.R. Wade, F. Duff, M. Lamb, and K. Jorga Predicting sustained virological response and anemia in chronic hapatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin Br J Clin Pharm 62 2006 699 709
15. M.S. Sulkowski, F. Poordad, M.P. Manns, J.P. Bronowicki, and K. Rajender Reddy et al. Anemia during treatment with peginterferon alfa-2b/ribavirin and boceprevir: analysis from the SPRINT-2 trial Hepatology 57 2013 974 984
16. M.S. Sulkowski, R. Reddy, N.H. Afdahl, A.M. Di Bisceglie, S. Zeuzem, and F. Poordad et al. Anemia had no effect on efficacy outcomes in treatment-naïve patients who received telaprevir-based regimens in the ADVANCE and ILLUMINATE phase 3 studies J Hepatol 54 Suppl. 1 2011 S195
17. M.L. Shiffman, M.G. Ghany, T.R. Morgan, E.C. Wright, G.T. Everson, and K.L. Lindsay et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C Gastroenterology 132 2007 103 112
18. D.T. Dieterich, R. Wasserman, N. Brau, T.I. Hassanein, E.J. Bini, and P.J. Bowers et al. Once weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa Am J Gastroenterol 98 2003 2491 2499
19. N.H. Afdhal, D.T. Dieterich, P.J. Pockros, E.R. Schiff, M.L. Shiffman, and M.S. Sulkowski et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study Gastroenterology 126 2004 1302 1311
20. INCIVO™ (telaprevir) prescribing information. http://pi.vrtx.com/ files/uspi-telaprevir.pdf [last accessed 2 July, 2013].
21. Victreslis EU Smpc. http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Product-Information/human/002332/WC500109786.pdf [last accessed 2 July, 2013].
22. F. Poordad, E.J. Lawitz, R. Reddy, N.H. Afdhal, C. Hézode, and S. Zeuzem et al. A randomised trial comparing ribavirin dose reduction vs. erythropoietin for anemia management in previously untreated patients with chronic hepatitis C receiving boceprevir plus peginterferon/ribavirin J Hepatol 56 Suppl. 2 2012 S559
23. S.C. Gordon, A.J. Muir, V. Garg, and J. Henshaw Exposure-response relationships in telaprevir combination therapy in treatment-naïve genotype 1 chronic HCV patients J Hepatol 56 Suppl. 2 2012 S440